Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma

Journal of Thoracic Oncology

Volumn 5, Issue 4, 2010, Pages 479-483

  Yasumitsu, Akihiro ^a   Tabata, Chiharu ^a   Tabata, Rie ^b   Hirayama, Noriko ^a   Murakami, Aki ^a   Yamada, Shusai ^a   Terada, Takayuki ^a   Iida, Shinichiro ^a   Tamura, Kunihiro ^a   Fukuoka, Kazuya ^a   Kuribayashi, Kozo ^a   Nakano, Takashi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Hyogo Prefectural Tsukaguchi Hospital   (Japan)

Author keywords

Cytokine; Mesothelioma; Tumor marker

Indexed keywords

ASBESTOS; TUMOR MARKER; VASCULOTROPIN;

AGED; ARTICLE; ASBESTOSIS; BLOOD LEVEL; CANCER SCREENING; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 77950995278     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d2f008     Document Type: Article

References (28)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408.
2. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-1603.
3. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960;17:260-271.
4. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980;15:2736-2740. (Pubitemid 11210245)
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-2644. (Pubitemid 46606305)
6. Nowak AK, Lake RA, Kindler HL, et al. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002;29:82-96.
7. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-1616. (Pubitemid 37443528)
8. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564-1573. (Pubitemid 41434635)
9. Tabata C, Tabata R, Kadokawa Y, et al. Thalidomide prevents bleomycin- induced pulmonary fibrosis in mice. J Immunol 2007;179:708-714. (Pubitemid 46986590)
10. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-475. (Pubitemid 32266815)
11. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995;108:1122-1128.
12. Rake C, Gilham C, Hatch J, et al. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer 2009;100:1175-1183.
13. Frebourg T, Lerebours G, Delpech B, et al. Serum hyaluronate in malignant pleural mesothelioma. Cancer 1987;59:2104-2107. (Pubitemid 17077798)
14. Schouwink H, Korse CM, Bonfrer JM, et al. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 1999;25:25-32. (Pubitemid 29325003)
15. Tabata C, Tabata R, Hirayama N, et al. All-trans-retinoic acid inhibits tumor growth of malignant pleural mesothelioma in mice. Eur Respir J 2009;34:1159-1167.
16. Versnel MA, Claesson-Welsh L, Hammacher A, et al. Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene 1991;6:2005-2011. (Pubitemid 21924040)
17. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, et al. Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage- independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 1994;11:29-44. (Pubitemid 24310376)
18. Marzo AL, Fitzpatrick DR, Robinson BW, et al. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 1997;57: 3200-3207.
19. Mórocz IA, Schmitter D, Lauber B, et al. Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway. Br J Cancer 1994;70:850-856. (Pubitemid 24331076)
20. Galffy G, Mohammed KA, Dowling PA, et al. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res 1999;59: 367-371. (Pubitemid 29048869)
21. Edwards JG, Swinson DE, Jones JL, et al. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 2003;124:1916-1923.
22. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
23. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9: 685-693.
24. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676. (Pubitemid 36749215)
25. Masood R, Kundra A, Zhu S, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 2003;104:603-610. (Pubitemid 36337260)
26. Hamada N, Kuwano K, Yamada M, et al. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol 2005;175:1224-1231. (Pubitemid 41095011)
27. Li Q, Yano S, Ogino H, et al. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res 2007;13: 5918-5925. (Pubitemid 47583920)
28. Demirag F, Unsal E, Yilmaz A, et al. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 2005;128:3382-3387. (Pubitemid 41698667)